Endocrine Abstracts

Introduction: The treatment with tyrosine-kinase inhibitor drugs (1st line Lenvatinib) in patients with radioiodine-refractory differentiated thyroid cancer (I-131) and disease progression can be burdened by important side effects which often require suspension/reduction of the therapy and correct multidisciplinary management.Patients and methods: Clinical/histopathological characteristics, outcome, adverse events and the role of gender have been evaluat...

Objectives: Evaluate the benefit of postsurgical radioactive iodine (RAI) in patients with differentiated thyroid cancer (DTC) at low to intermediate risk of recurrent disease in whom not routinary use of RAI is recommendedMethods: We retrospectively evaluated 1316 patients with DTC diagnosed between 2009-2015. ATA low (LR) and intermediate (IR) risk were included in the study (PTC: tumor size > 1 cm, microscopic extrathyroidal invasion, <5 micro...

Objective: Clarify mechanisms determining thyroid homeostasis during pregnancy at hypothalamic-pituitary level.Methods: Retrospective analysis of 251 pregnant women. 220/251 euthyroid without thyroxine therapy (Group 1), 31/251 thyroidectomized under thyroxine replacement therapy (Group 2). Patients under thyroxine replacement therapy with a TSH between 0.4 and 4.0 were included in the study. Patients with combined T3/T4 therapy were excluded.<p clas...

Background: Hashimoto’s thyroiditis (HT) is the most common autoimmune disease worldwide. Prevalence of celiac disease (CD) is higher in HT patients and HT is the most prevalent coexisting disease in CD patients. In the last years, interest about gluten free diet (GFD) has increased for its supposed extraintestinal anti-inflammatory effect, so many patients with HT initiate GFD on their own.Objectives: Aim of this meta-analysis is to examine all qua...

Background: Graves’ disease (GD) is an autoimmune disorder of thyroid gland and is the first cause of hyperthyroidism. Radioactive iodine (RAI) therapy is the most used second- line treatment after failure of anti-thyroid drugs. The optimal RAI’s activity to be administered may be predetermined or calculated. Whether the latter is better is still a matter of debate.Aim: To compare the risk of persistent hyperthyroidism in GD patients treated wi...

Background: The use of radioiodine treatment (RAI) in cases categorized as low to intermediate risk papillary thyroid cancer (PTC) is still uncertain. Current guidelines recommend a selective use of RAI based upon the clinicopathologic features of each case. In this context, postoperative serum thyroglobulin (pTg) could be useful but the predictive role for recurrence and the optimal cut off value to be applied is not clearly established.Objectives: To d...

Background: The 2022 WHO Classification of Endocrine and Neuroendocrine Tumors has introduced, as other neuroendocrine neoplasms, new pathological features to classify medullary thyroid carcinoma (MTC) in low/high grade. However, whether it can be reliable in clinical practice should be confirm by further studies.Aim: To verify the predictive value of the 2022 WHO grading system in patients with MTC.Materials and Methods: Tumor tis...

Background: Tyrosine kinase inhibitors (TKIs) are modern antineoplastic molecules widely used in the medical treatment of many cancers including iodine refractory differentiated thyroid carcer (DTC) and advanced medullary thyroid cancer (MTC). In patients with thyroid gland, TKIs frequently cause a destructive and/or autoimmune thyroiditis with consequent hypothyroidism. However, authors have reported unexpected TSH increase or hypothyroidism even in patients with total thyroi...

Background and objective: Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence is available regarding practical management of mitotane treatment and its eventual combination with chemotherapy or radiotherapy. The aim of the study is to do a survey on the use of mitotane for advanced ACC in expert Italian centers, analyzing data of the LYSOSAFE database.Methods: Retrospective analysis of patients ...

Introduction: Mitotane and platinum-based chemotherapy are the main therapeutic choices for treating inoperable and/or metastatic adrenocortical carcinoma (ACC).Objective: To search for prognostic parameters of survival in patients with metastatic ACC treated with combined mitotane- and platinum-based chemotherapy.Patients: One hundred and thirty one consecutive patients with metastatic ACC treated at the Gustave-Roussy Institute (...